The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation
Author:
Open Access
- 15 December 2021
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-13
Abstract
Background: Loss of prostate cancer differentiation or de-differentiation leads to an untreatable disease. Patient survival would benefit if this can be prevented or reversed. Cancer de-differentiation transforms luminal-like (differentiated) adenocarcinoma into less luminal-like and more stem-like (undifferentiated) small cell carcinoma through a sequential activation of stem cell transcription factors (scTF) POU5F1, LIN28A, SOX2 and NANOG. Like stem cells, prostate small cell carcinoma express this quartet of scTF as well as a 10-fold lower level of β2-microglobulin (B2M) than that of differentiated cell types. In organ development, prostate stromal mesenchyme cells mediate epithelial differentiation in part by secreted factors. Methods: The identified prostate stromal-specific factor proenkephalin (PENK) was cloned, and transfected into scTF+B2Mlo stem-like small cell carcinoma LuCaP 145.1, reprogrammed luminal-like scTF−B2Mhi LNCaP, and luminal-like scTF−B2Mhi adenocarcinoma LuCaP 70CR. The expression of scTF, B2M and anterior gradient 2 (AGR2) was analyzed in the transfected cells. Results: PENK caused down-regulation of scTF and up-regulation of B2M to indicate differentiation. When transfected into reprogrammed LNCaP, PENK reversed the reprogramming by down-regulation of scTF with attendant changes in cell appearance and colony morphology. When transfected into LuCaP 70CR, PENK up-regulated the expression of adenocarcinoma antigen AGR2, a marker associated with cancer cell differentiation. Conclusions: Prostate cancer cells appear to retain their responsiveness to stromal PENK signaling. PENK can induce differentiation to counter de-differentiation caused by scTF activation. The many mutations and aneuploidy characteristic of cancer cells appear not to hinder these two processes. Loss of prostate cancer differentiation is like reprogramming from luminal-like to stem-like.Keywords
This publication has 36 references indexed in Scilit:
- Prostate cancer cell phenotypes based on AGR2 and CD10 expressionLaboratory Investigation, 2013
- Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancersProceedings of the National Academy of Sciences, 2011
- Lineage relationship of prostate cancer cell types based on gene expressionBMC Medical Genomics, 2011
- Differential Inductive Signaling of CD90+ Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme CellsCancer Microenvironment, 2011
- Differential expression of anterior gradient gene AGR2 in prostate cancerBMC Cancer, 2010
- CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarkerLaboratory Investigation, 2010
- Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomesBMC Cancer, 2009
- Gene expression down-regulation in CD90+prostate tumor-associated stromal cells involves potential organ-specific genesBMC Cancer, 2009
- Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostateBMC Genomics, 2008
- The urologic epithelial stem cell database (UESC) – a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladderBMC Urology, 2007